Antisoma completes ovarian cancer trial enrollment

Antisoma (LSE:ASM; NASD-EU:ASOM) completed enrollment in its Phase III SMART trial of pemtumomab in 420 patients with ovarian cancer. In August, the trial's Data Safety Monitoring Committee recommended continuation of the trial. Last year, the FDA requested a higher level of statistical significance for the survival endpoint, and ASM enrolled additional patients. ...